XBIT — XBiotech Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1626878 ·
Last close
$1.78
Market Cap
$54.27M
52W High
$2.73
52W Low
$1.78
ADV30
84,173
Next earnings
—
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,319,000 -4,460,000 128,611,000 105,037,000 4,546,000
Jun 2026 0 — -6,146,000 -6,728,000 133,651,000 109,528,000 5,190,000
Mar 2026 0 — -6,274,000 -5,505,000 139,836,000 115,459,000 4,819,000
Dec 2025 0 — -29,755,000 -26,892,000 150,082,000 125,551,000 9,732,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-40,695,000
Investing CF
$-139,000
Financing CF
$0
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-148,610,000
Inventory
—
Receivables
$291,000
ST Investments
—
EBIT TTM
$-44,860,000
Pretax Income TTM
$-44,860,000
Interest Exp TTM
$0
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -55,685,000 -45,540,000 150,082,000 9,732,000 140,350,000 -39,920,000
Dec 2024 0 -42,471,000 -38,531,000 199,093,000 16,825,000 182,268,000 -30,963,000
Dec 2023 0 -37,510,000 -24,557,000 226,615,000 7,769,000 218,846,000 -18,725,000
Dec 2022 4,010,000 -34,490,000 -32,900,000 246,103,000 5,701,000 240,402,000 -14,824,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$8,013,000
NetIncome TTM
$-45,133,000
OpCashFlow TTM
—
Assets (Latest)
$133,651,000
Forward EPS
$0.13

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.73 · call volume: 20 · put volume: 10
Expected Move to 2027-01-15: ±$0.80 (46.24%) — implied range $0.93 – $2.53 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
QUCY Quantum Cyber N.V. $54.38M $0.62 —
INCR Intercure Ltd. $54.16M $3.61 —
VRCA Verrica Pharmaceuticals Inc. $53.94M $3.14 —
HRTX HERON THERAPEUTICS, INC. /DE/ $53.70M $0.28 —
IBO IMPACT BIOMEDICAL INC. $53.31M $6.17 —

News headlines (Yahoo Finance, 1h cache)

XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
2026-10-19 13:00 · Yahoo
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
2026-06-15 13:00 · Yahoo
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
2026-10-23 13:17 · Yahoo
3 Promising Penny Stocks With Market Caps Over $30M
2025-12-19 18:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.